Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ucb S.A. (OP: UCBJF ) 194.85 UNCHANGED Streaming Delayed Price Updated: 12:20 PM EST, Jan 7, 2025 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ucb S.A. Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside November 20, 2024 UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. Via Benzinga FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease November 20, 2024 FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement. Via Benzinga Exposures Product Safety Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial September 24, 2024 UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48... Via Benzinga Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage September 10, 2024 Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets. Via Benzinga Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB August 29, 2024 Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... Via Benzinga Exposures Product Safety UCB's Rare Childhood Epilepsy Drug Scores FDA Approval March 28, 2022 Via Benzinga Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies August 26, 2024 UCB announces a $680 million strategic divestment deal in China, selling its neurology and allergy business to CBC Group and Mubadala while focusing on innovative therapies in the region. Via Benzinga There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target January 02, 2024 Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of... Via Benzinga Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst September 28, 2023 Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. Via Benzinga Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts August 31, 2023 Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and Via Benzinga FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults June 27, 2023 The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or... Via Benzinga Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path February 14, 2023 Via Benzinga Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane February 08, 2022 Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have Via Benzinga UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study January 21, 2022 UCB SA (OTC: UCBJF) posted topline results from the Phase 3 BE COMPLETE study evaluating Bimzelx (bimekizumab) for active psoriatic arthritis patients who were... Via Benzinga UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights January 19, 2022 Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion,... Via Benzinga UCB Gets EU Approval For Bimekizumab In Psoriasis August 25, 2021 The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in... Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
